A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

ClinicalTrials.gov ID: NCT07258836

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07258836. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label Study to Evaluate the Safety, Biodistribution, Imaging Characteristics, and Radiation Dosimetry of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.

Study identification

NCT ID: NCT07258836
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 41 participants

Conditions and interventions

Conditions

Interventions

LY4214835 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 22, 2025 (Actual)
Primary completion: Dec 2027 (Estimated)
Completion: Dec 2027 (Estimated)
Last update posted: Nov 6, 2026

2025 – 2027

United States locations

U.S. sites: 6
U.S. states: 4
U.S. cities: 6

Facility	City	State	ZIP	Site status
Invicro	New Haven	Connecticut	06510	Completed
Boston Medical Center	Boston	Massachusetts	02118	Not yet recruiting
Massachusetts General Hospital (MGH)	Charlestown	Massachusetts	02129	Not yet recruiting
BAMF Health Inc.	Grand Rapids	Michigan	49503	Not yet recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Ichor Research	Syracuse	New York	13210	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07258836, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 6, 2026 · Synced Nov 14, 2026